share_log

Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025

Benzinga ·  Sep 25 19:03
Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment